Hangzhou, China

Shuqian Jing

USPTO Granted Patents = 9 

 

 

Average Co-Inventor Count = 6.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Hangzhou, CN (2018 - 2023)
  • Zhejiang, CN (2023)

Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Shuqian Jing: Innovator in Pharmaceutical Antibody Development

Introduction

Shuqian Jing is a prominent inventor based in Hangzhou, China, known for his significant contributions to the field of pharmaceutical sciences. He holds a total of nine patents, showcasing his innovative approach to developing therapeutic solutions.

Latest Patents

Among his latest patents are the APJ antibody and its fusion protein with Elabela, which are designed to treat, prevent, or alleviate symptoms of pulmonary arterial hypertension, pulmonary hypertension, and heart failure. Additionally, he has developed a GIPR antibody and its fusion protein with GLP-1, aimed at addressing non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes, and obesity. These advancements highlight his commitment to improving health outcomes through innovative pharmaceutical compositions.

Career Highlights

Shuqian Jing has worked with notable companies such as Gmax Biopharm LLC and Gmaz Biopharm LLC, where he has played a crucial role in advancing research and development in biopharmaceuticals. His expertise in antibody development has positioned him as a key figure in the industry.

Collaborations

Shuqian has collaborated with esteemed colleagues, including Cheng Zhang and Hua Zhang, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Shuqian Jing's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His patents and collaborations reflect a dedication to addressing critical health challenges through advanced therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…